Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet #Gilead #Sciences #Diversification #Strategy #Derisked

Gilead, LEO Pharma partner to develop programs for inflammatory diseases By Reuters

(Reuters) – Gilead Sciences (NASDAQ:) said on Saturday that it entered into a partnership with Denmark’s…

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

— Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral…

Morgan Stanley upgrades Gilead on HIV treatment growth By Investing.com

Investing.com — Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:) to “overweight” from “equal weight,” raising its price…

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise #Gilead #Sciences #Preview #Buy #Thriving…